Durability of treatment response in patients with moderate to severe psoriasis following withdrawal from or a dose reduction in adalimumab therapy

被引：0
|
作者：
Blum, R
Lebwohl, M
Gottlieb, A
Chen, D
机构：
[1] Mt Sinai Sch Med, New York, NY USA
[2] Univ Med & Dent New Jersey, New Brunswick, NJ USA
[3] Abbott Labs, Abbott Pk, IL 60064 USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2005年 / 52卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：P180 / P180
页数：1
相关论文
共 50 条
  • [1] Fatigue outcomes following withdrawal from and retreatment with adalimumab among patients maintained on adalimumab for moderate to severe psoriasis
    Papp, Kim
    Wu, Eric
    Goldblum, Orin
    Gupta, Shiraz
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2011, 64 (02) : AB157 - AB157
  • [2] Durability of treatment response following withdrawal from etanercept in psoriasis patients
    Gottlieb, A
    Gordon, K
    Wang, A
    Zitnik, R
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2004, 122 (03) : A51 - A51
  • [3] Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy
    Papp, K.
    Crowley, J.
    Ortonne, J. -P.
    Leu, J.
    Okun, M.
    Gupta, S. R.
    Gu, Y.
    Langley, R. G.
    BRITISH JOURNAL OF DERMATOLOGY, 2011, 164 (02) : 434 - 441
  • [4] Adalimumab retreatment restores clinical response in patients with moderate to severe psoriasis following relapse
    Gordon, Kenneth B.
    Gottlieb, Alice B.
    Okun, Martin M.
    Wang, Yuzhen
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2012, 66 (04) : AB184 - AB184
  • [5] Time to Loss of Response following Withdrawal of Ixekizumab in Patients with Moderate-to-Severe Psoriasis
    Papp, Kim
    Paul, Carle
    Kleyn, C. Elise
    Huang, Yu-Huei
    Tsai, Tsen-Fang
    Schuster, Christopher
    El Baou, Celine
    Toth, Agoston
    Riedl, Elisabeth
    Mrowietz, Ulrich
    ACTA DERMATO-VENEREOLOGICA, 2022, 102
  • [6] The effect of adalimumab treatment for moderate to severe psoriasis on concurrent response for both psoriasis and psoriatic arthritis
    Mease, Philip
    Signorovitch, James
    Mulani, Parvez
    Gupta, Shiraz
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2009, 60 (03) : AB178 - AB178
  • [7] Drug focus: adalimumab in the treatment of moderate to severe psoriasis
    Vena, Gino A.
    Cassano, Nicoletta
    BIOLOGICS-TARGETS & THERAPY, 2007, 1 (02): : 93 - 103
  • [8] Adalimumab for treatment of moderate to severe psoriasis and psoriatic arthritis
    Bongiorno, M. R.
    Pistone, G.
    Doukaki, S.
    Arico, M.
    DERMATOLOGIC THERAPY, 2008, 21 : S15 - S20
  • [9] Adalimumab treatment for moderate psoriasis reduces the risk of transitioning to severe psoriasis
    Papp, Kim
    Signorovitch, James
    Mulani, Parvzez
    Gupta, Shiraz
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2009, 60 (03) : AB181 - AB181
  • [10] Reduction in C-reactive protein levels with adalimumab therapy in patients with moderate to severe hand and/or foot psoriasis
    Leonardi, Craig L.
    Unnebrink, Kristina
    Valdecantos, Wendell C.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB266 - AB266
12345